Maravai LifeSciences Holdings

mRNA And Cell Therapy Demand Will Transform Global Markets

AnalystHighTarget

Not Invested

Consensus Narrative from 8 Analysts

Published

06 Aug 25

Updated

16 Aug 25

AnalystHighTarget's Fair Value

US$5.00

47.8% undervalued

16 Aug

US$2.61

-71.8%

26.7%

Author's Valuation

US$5.0

47.8% undervalued

AnalystHighTarget Fair Value

Narrative

Updates0

AnalystHighTarget Fair Value

US$5.0

47.8% undervalued

Future estimation in

% p.a.

Decrease

Increase

Current revenue growth rate

4.02%

Life Sciences revenue growth rate

0.33%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

8.24%

Calculation

US$19.99m

Earnings '28

48.44x

PE Ratio '28

US$968.41m

Market Cap '28

US$968.41m

Market Cap '28

152.59m

No. shares '28

US$6.35

Share Price '28

US$6.35 Share Price '28

Discounted to 2025 @ 8.28% p.a.

US$5.00

Fair Value '25